The Changes of Interleukin 17 levels On Pulmonary Tuberculosis Patients with AFB Smear-Positive After 2 Months Anti Tuberculosis Drugs Treatment

Andy Sulaiman Siregar, Soedarsono Soedarsono

Abstract


Background: Tuberculosis still remain as a health problem in the world. No specific biomarkers can be used to monitor the rapid response to TB therapy. This study aims to assess the change of IL-17 levels in pulmonary tuberculosis patients with AFB smear-positive before and after 2 months of anti tuberculosis drugs (ATD) treatment.
Method: Design of study is analytic observational with prospective cohort. The subject include 17 new cases of pulmonary tuberculosis patients with AFB smear-positive in Soetomo Hospital Surabaya from July - October 2016. Plasma levels of IL-17 were measured using ELISA technique before treatment and 2 months after the ATD therapy.
Results: The mean levels of IL-17 before treatment is 3.510 pg / ml (2.087- 5.051 pg/ml). There were significantly decreament (p = 0.001 <0.005) after 2 months of treatment with the value is 2.574 pg/ml (1.771 - 4,095 pg /ml). There was no significant correlation between the levels of IL-17 with a rate of sputum smear positivity in patients with smear-positive pulmonary TB (p-value 0.259). There was no significant correlation between sputum conversion with decreased levels of IL-17 after 2 months of treatment. (P-value 0.486).
Conclusions:Levels of IL-17 decreased significantly after 2 months of therapy. IL-17 has not been fully proven to be used as a biomarker evaluation and the success of TB treatment. However, IL-17 play quite significant role at TB immunopathogenesis and protective immunity against TB infection. (J Respir Indo. 2018; 38: 219-26)

Keywords


Interleukin 17; pulmonary tuberculosis, success of therapy; positivity of sputum

Full Text:

PDF

References


World Health Organization. Global Tuberculosis Report. [Online]. 2015 [Cited 2016 October 1]. Available from: http://www.who.int/tb.data

Kemenkes RI. Pedoman nasional pengendalian tuberkulosis. Jakarta;2014

Soedarsono, Kusmiati T. Manifestasi klinis tuberkulosis. Dalam Mertaniasih N, Khoendhori E, Kusumaningrum D, Editor. Buku Ajar Tuberkulosis Diagnostik Mikrobiologis. Edisi 1. LP3 UNAIR dan Pusat Penerbitan dan Percetakan UNAIR Surabaya. 2013.p.61-7

Hasan H. Tuberkulosis paru. Dalam : Buku Ajar Ilmu Penyakit Paru. M. Jusuf W, Winariani, Slamet H (Editor). Dep. Ilmu Penyakit Paru FKUNAIR. Cetakan II.2010.p.9-17

Kashyap S & Sarkar M. Pulmonary tuberculosis: clinical features and diagnosis (Chapter 8). In Handbook of pulmonary & critical care medicine. SK Jindal (editors in chief). Jaypee Brothers Medical Publisher. 2012.p.54-9

Mihret A & Abebe M, Cytokines and chemokines as biomarkers of tuberculosis. J Mycobac Dis. 2013;3:2-4

Mensah GI. Biomarkers for TB treatment response and cure; Immunological profiles of individuals infected by Mycobacterium tuberculosis complex in Ghana. 2014.p.31-2

Adrian TBR, Montiel JL, Fernandez G, Valecillo A. Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. World Journal of immunology. 2015;5:16-50.

Cooper AM. Is IL-17 required to control tuberculosis? In: Quesniaux V, Ryffel B, Padova F, editors. IL-17, IL-22 and their producing cells: role in inflammation and autoimmunity. 2nd edition. New York: Springer Basel. 2013;189-205

Dheda K, Schwander SK, Zhu B, Van Zyl-Smith RN, Zhang Y. The immunology of tuberculosis: From bench to bedside. Respirology.2010;15:433–50

Chen CYC, Chin CH, Liu SF, et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Disease Markers. 2011;31:101–10

Kementerian Kesehatan RI. Profil Kesehatan Indonesia Tahun 2014. [Online]. 2015 [Cited 2016 October 1]. Available from: http://www.depkes.go.id/pusdatin/profil-kesehatan-indonesia/profilkesehatan-indonesia-2014

WHO. TB women factsheet. [Online]. 2015 [Cited 2016 Sep 1]. Available from: http://www.who.int/tb

Human IL-17A. Legend MaxTM Elisa kit with precoated plates. Biolegend, inc. [Online]. 2014 [Cited 2016 Sep 30]. Available from: http://www.biolegend.com

Emizola F, Sugiri YJ, Sartono TR, Al Rasyid H. Kadar Interleukin 10 dan Interleukin 17 selama 6 bulan terapi anti tuberkulosis oral pada pasien tuberkulosis paru serta hubungannya dengan keberhasilan terapi. J Respir Indo. 2015;1:12-8

Xu LC, Cui G, Jia H, et al. Decreased IL‑17 during treatment of sputum smear positive pulmonary tuberculosis due to increased regulatory T cells and IL‑10.J Transl Med. 2016;14:179

Frangen T, Bogdanski D, Schinkel C, Roetman B, Licke TK, Muhr G. Systemic Il-17 after severe injuries. Shock. 2008;29:462-7

Lyadova IV, Panteleev AV. Th1 and Th17 in tuberculosis: protection, pathology, and biomarkers. Review Article. Mediators of Inflammation. 2015.p.1-13

Matthews K, Wilkinson KA, Kalsdorf, et al. Predominance of interleukin -22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis. 2011;91:587-93

Basile JI, Geffner LJ, Romero MM, et al. Outbreaks of Mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. Journal of Infectious Diseases. 2011;204:1054-64




DOI: https://doi.org/10.36497/jri.v38i4.23

Refbacks

  • There are currently no refbacks.





Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org


An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License

Statcounter